Circle Pharma

At #AACR26, we will share three presentations highlighting new data across our cyclin inhibitor programs, including an oral plenary featuring early clinical activity for CID-078, our first-in-class oral macrocyclic cyclin A/B RxL inhibitor. Details: circlepharma.com/circle-pharma-…

We are pleased to share our publication in the Journal of Medicinal Chemistry highlighting the optimization of our first-in-class oral cyclin A/B RxL inhibitors: pubs.acs.org/doi/10.1021/ac…. PR here: circlepharma.com/circle-pharma-…

We look forward to connecting with the investment community at upcoming investor conferences to discuss our progress in advancing first-in-class cyclin-targeted therapies for #cancer. circlepharma.com/circle-pharma-…

On #IDWGS, we’re proud to recognize the women at Circle whose expertise and collaboration help drive our science forward. We’re excited to spotlight members of our team and share their #STEM perspectives. Read here: linkedin.com/pulse/celebrat…

On #WorldCancerDay, we recognize that every cancer journey is unique. With 2M+ new diagnoses expected in the U.S. this year (@AmericanCancer), continued innovation remains clear. We’re harnessing the power of macrocycles to help transform #cancer treatment -circlepharma.com

This month, our VP of Biology Research Pablo Garcia retired after more than 11 years at Circle and over 30 years in drug discovery. Read the full story here: linkedin.com/feed/update/ur…

#JPM26: CEO David Earp will provide an overview of our #oncology pipeline, including CID-078, a first-in-class oral macrocyclic cyclin A/B RxL inhibitor in Phase 1 clinical development & CID-165, a first-in-class oral macrocyclic cyclin D1 RxL inhibitor. circlepharma.com/circle-pharma-…

As 2025 comes full circle, we’re reflecting on the progress made possible by our team, partners and community. This year brought meaningful #oncology milestones and we’re grateful to everyone who has been part of the journey. We’re excited for what’s ahead in 2026!

We are pleased to announce the nomination of CID-165, a first-in-class, orally bioavailable macrocyclic cyclin D1 RxL inhibitor, as the development candidate for our second #oncology program. Read the full release: circlepharma.com/circle-pharma-…

With 20+ years of experience and an established #oncology track record in clinical leadership and drug approvals, we're proud to welcome Anne Borgman, M.D., to Circle as chief medical officer! Read the full release: circlepharma.com/circle-pharma-…

Jim Aggen, our VP, Med Chem will be at #DDCEurope, presenting our macrocycle approach to undruggable #oncology targets, showcasing our development of oral, cell-permeable macrocyclic cyclin A/B RxL inhibitors. Learn more: bit.ly/48OKbGx

CEO David Earp and CFO Rob Lauzen will participate in upcoming investor conferences this November. We look forward to connecting in London to discuss the science and strategy behind our targeted macrocycle therapies for #cancer. Learn more: circlepharma.com/circle-pharma-…

We're thrilled to welcome Rob Lauzen as our CFO. With deep financial expertise and broad experience within the life sciences industry, Rob will help us build on our strong momentum and drive long-term growth. Read more here: circlepharma.com/circle-pharma-…

We’re presenting preclinical data from our cyclin D1-driven program for #cancer at the #TripleMeeting. We are on track to declare a development candidate by the end of 2025. Read the details: circlepharma.com/circle-pharma-…

Too much cyclin D1 can cause cells to grow out of control, leading to cancer. Via MXMO™ platform, our oral macrocycle cyclin D1 RxL inhibitors can selectively disrupt key protein interactions involving cyclin D1 - a key step in our development of targeted therapies for #cancer.

Cyclin D1 helps cells grow and divide by activating CDKs. When too much cyclin D1 is made, it can drive uncontrolled cell growth causing #cancer. At Circle Pharma, we’re developing targeted therapies for cancer including those driven by cyclin D1.

We’re proud to share an upcoming poster presentation highlighting our preclinical anti-tumor potential of cyclin D1 RxL inhibition at the #TripleMeeting #AACR #NCI #EORTC in Boston. Learn more: circlepharma.com/circle-pharma-…

This #ChildhoodCancerAwarenessMonth, we’re reminded why our work at Circle Pharma is so critical. At @AACR, we presented new preclinical data with our lead program, CID-078, as a potential novel therapeutic option in pediatric cancers. Read the abstract: aacrjournals.org/cancerres/arti…

We are pleased to share an upcoming poster presentation highlighting the potential of CID-078 as a novel therapeutic option in pediatric cancers at the @AACR Special Conference on Pediatric Cancer, taking place from Sept. 25-28 in Boston, MA. Learn more: circlepharma.com/circle-pharma-…

We are excited to announce an agreement with @EliLillyandCo that enables Circle Pharma to use Lilly TuneLab, a pioneering #AI and #ML platform designed to accelerate the development of new medicines. Read the full press release: circlepharma.com/circle-pharma-…